GNRX

Fund Description
VanEck Vectors Generic Drugs ETF (GNRX) seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the Indxx Global Generics & New Pharma Index (IGNRXT), which is intended to track the overall performance of companies that derive a significant proportion of their revenues or that have the potential to derive a significant proportion of their revenues from the generic drug industry, or that have a primary business focus on the generic drug industry. The Index is a rules based, modified capitalization weighted index. The Index includes exchange-listed companies, on a global basis, that derive a significant proportion of their revenues (or that have the potential to derive a significant proportion of their revenues) from the generic drug industry, or that have a primary business focus on the generic drug industry. The generic drug industry, as defined by the Index Provider, includes any company involved in the research, development, production, manufacturing or sale of generics, supergenerics, biosimilars, biobetters or their active pharmaceutical ingredients ( APIs ).
Fund Profile
Fund Name VanEck Vectors Generic Drugs ETF
Fund Exchange Ticker GNRX
Fund Sponsor Van Eck Associates Corporation
Fund ISIN US92189F5778
Net Expense Ratio 0.57 %
Fund Inception Date 12 January 2016
Fund Legal Structure ETF (Open end fund)
Exchange NASDAQ
Listing Country Code US
Fund Investment Objective
ETF Type Specific Global or ExUS Equities - Industry Sector
Asset Class Equities (Stocks)
Index Linked Passive
Index Name Indxx Global Generics & New Pharma Index
Index Provider Indxx LLC
Currency Hedged No
Inverse / Leveraged Not Applicable
Developed / Emerging Funds Combining Developed & Emerging Exposure
Market Capitalization Range Broad Market / Multi-Cap
Growth Value Core / Blend
Continent Not Applicable
Key Statistics
Return As of Date 18 January 2019
Asset Under Management 3.27 Million (USD)
1 Month Total Return 2.12 %
Year To Date Return 5.07 %
1 Year Total Return -12.91 %
3 Year Annualized Total Return -2.80 %
NAV 21.78
Share Outstanding 150,000
Top 10 Holdings (18 January 2019)
Constituent Name Constituent Ticker Constituent Type Weighting
PFIZER INC PFE EQUI 0.0941
IQVIA HOLDINGS INC IQV EQUI 0.0813
CELLTRION INC 068270 EQUI 0.0671
LONZA GROUP AG-REG LONN EQUI 0.0658
TEVA PHARMACEUTICAL-SP ADR TEVA EQUI 0.0585
MYLAN NV MYL EQUI 0.0468
SUN PHARMACEUTICAL INDUS SUNP EQUI 0.0387
KYOWA HAKKO KIRIN CO LTD 4151 EQUI 0.0352
SINO BIOPHARMACEUTICAL 1177 EQUI 0.0333
CSPC PHARMACEUTICAL GROUP LT 1093 EQUI 0.0331